{"id":"placebo-for-risedronate","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reaction"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL1654","moleculeType":"Small molecule","molecularWeight":"305.10"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Placebo is used as a control in clinical trials to compare the efficacy of active treatments. It does not have any therapeutic effect and is not intended to treat any medical condition.","oneSentence":"Placebo does not have a known mechanism of action as it is an inactive substance.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:16.325Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis prevention in postmenopausal women"}]},"trialDetails":[{"nctId":"NCT00092014","phase":"PHASE3","title":"A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2002-09-01","conditions":"Postmenopausal Osteoporosis","enrollment":1053},{"nctId":"NCT03861091","phase":"PHASE2","title":"Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRT","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2019-07-12","conditions":"Lung Neoplasm","enrollment":84},{"nctId":"NCT00445575","phase":"PHASE2, PHASE3","title":"Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of Bone","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2007-07-22","conditions":"Fibrous Dysplasia of Bone","enrollment":80},{"nctId":"NCT03411902","phase":"PHASE4","title":"Weight Loss With Risedronate for Bone Health","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2018-06-15","conditions":"Bariatric Surgery Candidate, Bone Loss, Weight Loss","enrollment":24},{"nctId":"NCT00452439","phase":"PHASE3","title":"A Study of Actonel for the Prevention of Bone Loss","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2004-02","conditions":"Leukemia, Lymphoma","enrollment":72},{"nctId":"NCT01406444","phase":"NA","title":"IGF-1 and Bone Loss in Women With Anorexia Nervosa","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2011-10","conditions":"Anorexia Nervosa, Osteopenia, Osteoporosis","enrollment":148},{"nctId":"NCT01709110","phase":"PHASE4","title":"VERtebral Fracture Treatment Comparisons in Osteoporotic Women","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2012-10","conditions":"Postmenopausal Osteoporosis","enrollment":1366},{"nctId":"NCT00266708","phase":"PHASE1, PHASE2","title":"Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.","status":"COMPLETED","sponsor":"Montefiore Medical Center","startDate":"2002-10","conditions":"Renal Transplant Osteodystrophy","enrollment":60},{"nctId":"NCT01575873","phase":"PHASE3","title":"Efficacy and Safety of Denosumab Compared With Risedronate in Individuals Taking Glucocorticoids","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-28","conditions":"Steroid-induced Osteopor, Glucocorticoid-induced Ostepor","enrollment":795},{"nctId":"NCT00859027","phase":"PHASE4","title":"Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer","status":"COMPLETED","sponsor":"UConn Health","startDate":"2003-01","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT02063854","phase":"PHASE2, PHASE3","title":"A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets","status":"COMPLETED","sponsor":"Takeda","startDate":"2014-02","conditions":"Involutional Osteoporosis","enrollment":871},{"nctId":"NCT00043069","phase":"PHASE3","title":"Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2002-11","conditions":"Osteoporosis, Prostate Cancer","enrollment":71},{"nctId":"NCT00054418","phase":"PHASE3","title":"Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast Cancer","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2003-03","conditions":"Breast Cancer, Osteoporosis","enrollment":216},{"nctId":"NCT00221299","phase":"PHASE4","title":"Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use","status":"COMPLETED","sponsor":"University of California, Davis","startDate":"2005-09","conditions":"Osteoporosis","enrollment":60},{"nctId":"NCT00772395","phase":"PHASE4","title":"Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip Arthroplasty","status":"COMPLETED","sponsor":"Danderyd Hospital","startDate":"2006-04","conditions":"Bone Loss","enrollment":78},{"nctId":"NCT01611571","phase":"PHASE3","title":"Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis","status":"COMPLETED","sponsor":"Columbia University","startDate":"2003-12","conditions":"Osteoporosis","enrollment":31},{"nctId":"NCT00859703","phase":"PHASE3","title":"Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast Cancer","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2009-11","conditions":"Breast Cancer, Menopause, Osteopenia","enrollment":20},{"nctId":"NCT00106028","phase":"PHASE3","title":"Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2004-11","conditions":"Osteogenesis Imperfecta","enrollment":143},{"nctId":"NCT00577395","phase":"PHASE4","title":"Bone Microarchitecture in Osteopenic Postmenopausal Women","status":"TERMINATED","sponsor":"Warner Chilcott","startDate":"2008-07","conditions":"Osteoporosis","enrollment":13},{"nctId":"NCT01806792","phase":"PHASE3","title":"Post-menopausal Women Osteoporosis(Phase III)","status":"COMPLETED","sponsor":"Hanlim Pharm. Co., Ltd.","startDate":"2009-11","conditions":"Postmenopausal Women Osteoporosis","enrollment":150},{"nctId":"NCT00447915","phase":"PHASE3","title":"Phase II/III Clinical Study of R484iv (Ibandronic Acid) for Primary Osteoporosis","status":"COMPLETED","sponsor":"Chugai Pharmaceutical","startDate":"2007-03","conditions":"Primary Osteoporosis","enrollment":1265},{"nctId":"NCT00103740","phase":"PHASE3","title":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-04","conditions":"Paget's Disease of Bone","enrollment":185},{"nctId":"NCT00051636","phase":"PHASE3","title":"Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2001-01","conditions":"Paget's Disease of Bone","enrollment":172},{"nctId":"NCT00426777","phase":"PHASE3","title":"Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer","status":"COMPLETED","sponsor":"CMX Research","startDate":"2007-01","conditions":"Prostate Cancer","enrollment":160},{"nctId":"NCT00386360","phase":"PHASE3","title":"Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning Method","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2006-04","conditions":"Osteopenia","enrollment":161},{"nctId":"NCT00619957","phase":"PHASE3","title":"Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With Osteoporosis","status":"COMPLETED","sponsor":"Warner Chilcott","startDate":"2002-06","conditions":"Other Osteoporosis","enrollment":285},{"nctId":"NCT00790101","phase":"PHASE4","title":"Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation","status":"TERMINATED","sponsor":"Sanofi","startDate":"2004-06","conditions":"Osteoporosis, Postmenopausal","enrollment":6},{"nctId":"NCT00345644","phase":"PHASE3","title":"Risedronate in Osteopenic Postmenopausal Women","status":"COMPLETED","sponsor":"Sanofi","startDate":"2006-03","conditions":"Osteoporosis","enrollment":156}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["once a month"],"phase":"phase_3","status":"active","brandName":"Placebo(for Risedronate)","genericName":"Placebo(for Risedronate)","companyName":"Hanlim Pharm. Co., Ltd.","companyId":"hanlim-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo does not have a known mechanism of action as it is an inactive substance. Used for Osteoporosis prevention in postmenopausal women.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}